Ayman K Hamouda

Dr. Ayman K Hamouda


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2005 in Biochemistry
Verified
Journal Article
Closed access
AHAyman K Hamouda
Ayman K Hamouda
DCDavid C. Chiara
David C. Chiara
DSDaniel Sauls
Daniel Sauls
JCJonathan B. Cohen
Jonathan B. Cohen
MBMichael P. Blanton
Michael P. Blanton

9 March 2006 in Biochemistry
Verified
Journal Article
Closed access
AHAyman K Hamouda
Ayman K Hamouda
MSMitesh Sanghvi
Mitesh Sanghvi
DSDaniel Sauls
Daniel Sauls
TMTina K. Machu
Tina K. Machu
MBMichael P. Blanton
Michael P. Blanton

9 January 2013 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
AHAyman K Hamouda
Ayman K Hamouda
TKTilia Kimm
Tilia Kimm
JCJonathan B. Cohen
Jonathan B. Cohen
Galanthamine and physostigmine are clinically used cholinomimetics that both inhibit acetylcholinesterase and also interact directly with and potentiate nAChRs. As with most nAChR-positive allosteric modulators, the location and number of their binding site(s) within nAChRs are unknown. In this study, we use the intrinsic photoreactivities of [3H]physostigmine and [3H]galanthamine upon irradiation at 312 nm to directly identify amino acids contributing to their binding sites in theTorpedo californicanAChR. Protein sequencing of fragments isolated from proteolytic digests of [3H]physostigmine- or [3H]galanthamine-photolabeled nAChR establish that, in the presence of agonist (carbamylcholine), both drugs photolabeled amino acids on the complementary (non-α) surface of the transmitter binding sites (γTyr-111/γTyr-117/δTyr172). They also photolabeled δTyr-212 at the δ-β subunit interface and γTyr-105 in the vestibule of the ion channel, with photolabeling of both residues enhanced in the presence of agonist. Furthermore, [3H]physostigmine photolabeling of γTyr-111, γTyr-117, δTyr-212, and γTyr-105 was inhibited in the presence of nonradioactive galanthamine. The locations of the photolabeled amino acids in the nAChR structure and the results of computational docking studies provide evidence that, in the presence of agonist, physostigmine and galanthamine bind to at least three distinct sites in the nAChR extracellular domain: at the α-γ interface (1) in the entry to the transmitter binding site and (2) in the vestibule of the ion channel near the level of the transmitter binding site, and at the δ-β interface (3) in a location equivalent to the benzodiazepine binding site in GABAAreceptors.

1 February 2017 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
ZGZuzana Gazova
Zuzana Gazova
OSOndrej Soukup
Ondrej Soukup
VHVendula Hepnarova
Vendula Hepnarova
KSKatarina Siposova
Katarina Siposova
LDLucie Drtinova
Lucie Drtinova
KKKamil Kuca
Kamil Kuca

1 June 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
AHAyman K Hamouda
Ayman K Hamouda
DSDeirdre S. Stewart
Deirdre S. Stewart
SHS. Shaukat Husain
S. Shaukat Husain
JCJonathan B. Cohen
Jonathan B. Cohen
Photoreactive derivatives of the general anesthetic etomidate have been developed to identify their binding sites in γ-aminobutyric acid, type A and nicotinic acetylcholine receptors. One such drug, [(3)H]TDBzl-etomidate (4-[3-(trifluoromethyl)-3H-diazirin-3-yl]benzyl-[(3)H]1-(1-phenylethyl)-1H-imidazole-5-carboxylate), acts as a positive allosteric potentiator of Torpedo nACh receptor (nAChR) and binds to a novel site in the transmembrane domain at the γ-α subunit interface. To extend our understanding of the locations of allosteric modulator binding sites in the nAChR, we now characterize the interactions of a second aryl diazirine etomidate derivative, TFD-etomidate (ethyl-1-(1-(4-(3-trifluoromethyl)-3H-diazirin-3-yl)phenylethyl)-1H-imidazole-5-carboxylate). TFD-etomidate inhibited acetylcholine-induced currents with an IC(50) = 4 μM, whereas it inhibited the binding of [(3)H]phencyclidine to the Torpedo nAChR ion channel in the resting and desensitized states with IC(50) values of 2.5 and 0.7 mm, respectively. Similar to [(3)H]TDBzl-etomidate, [(3)H]TFD-etomidate bound to a site at the γ-α subunit interface, photolabeling αM2-10 (αSer-252) and γMet-295 and γMet-299 within γM3, and to a site in the ion channel, photolabeling amino acids within each subunit M2 helix that line the lumen of the ion channel. In addition, [(3)H]TFD-etomidate photolabeled in an agonist-dependent manner amino acids within the δ subunit M2-M3 loop (δIle-288) and the δ subunit transmembrane helix bundle (δPhe-232 and δCys-236 within δM1). The fact that TFD-etomidate does not compete with ion channel blockers at concentrations that inhibit acetylcholine responses indicates that binding to sites at the γ-α subunit interface and/or within δ subunit helix bundle mediates the TFD-etomidate inhibitory effect. These results also suggest that the γ-α subunit interface is a binding site for Torpedo nAChR negative allosteric modulators (TFD-etomidate) and for positive modulators (TDBzl-etomidate).

15 September 2009 in Biochemistry
Verified
Journal Article
Closed access
DCDavid C. Chiara
David C. Chiara
AHAyman K Hamouda
Ayman K Hamouda
MZMichael R. Ziebell
Michael R. Ziebell
LMLuis A. Mejia
Luis A. Mejia
GGGalo Garcia
Galo Garcia
JCJonathan B. Cohen
Jonathan B. Cohen